Can you provide a step-by-step algorithm for interpreting Pap smear results in Ontario, Canada?

Pap Smear Interpretation Algorithm for Ontario, Canada

In Ontario, cervical cytology results should be interpreted using the Bethesda System classification, with management decisions based on the specific cytologic finding, patient age, and HPV testing status when available.

Cytology Result Categories (Bethesda System)

The Pap smear results are classified from lowest to highest cancer risk as follows 1:

1. Negative for intraepithelial lesion or malignancy (NILM) - Normal result
2. Atypical squamous cells of undetermined significance (ASC-US) - Lowest risk abnormality
3. Low-grade squamous intraepithelial lesion (LSIL)
4. Atypical squamous cells, cannot exclude high-grade (ASC-H)
5. High-grade squamous intraepithelial lesion (HSIL)
6. Invasive carcinoma - Highest risk

Management Algorithm by Result

Unsatisfactory Specimen

• Repeat cytology even if HPV-negative
• Alternative: Colposcopy is an option for women ≥30 years 1

NILM (Normal)

• Continue routine screening per Ontario guidelines 2
• Screening interval depends on age and whether cotesting (cytology + HPV) was performed

ASC-US

• Reflex HPV testing is the preferred approach
• If HPV positive → Colposcopy
• If HPV negative → Return to routine screening
• Alternative if HPV unavailable: Repeat cytology in 6-12 months or proceed to colposcopy 1

LSIL

• Colposcopy with directed biopsies for evaluation
• Management follows the principle of "similar management for similar risks" 1

ASC-H

• Immediate colposcopy due to higher cancer risk
• Colposcopically directed biopsies required 1

HSIL

• Immediate colposcopy with directed biopsies
• This represents precancerous changes requiring definitive evaluation 1

Invasive Carcinoma

• Urgent colposcopy and gynecologic oncology referral
• Requires comprehensive staging and treatment planning

Colposcopy Technique

When colposcopy is indicated 1:

• Apply 3-5% acetic acid solution to cervix
• Visualize through magnification (10x-16x)
• Perform directed biopsies of abnormal areas
• Adequate examination: Entire squamocolumnar junction visualized (transformation zone seen completely)
• If adequate examination achieved, endocervical curettage not required
• Biopsy determines extent of disease (e.g., CIN 3)

Key Ontario-Specific Considerations

Based on the 2012 Ontario guideline 2:

• Ontario has an organized screening program with evidence-based recommendations
• The province provides invitations to women in target populations
• HPV testing integration was being implemented (interim recommendations existed until HPV testing funded)

Critical Pitfalls to Avoid

1. Do not screen women <21 years - screening not recommended regardless of sexual activity 1
2. Do not use HPV testing as stand-alone screening in women 21-29 years 1
3. Do not perform annual screening - no longer recommended for any age group 1
4. HPV-vaccinated women require same screening as unvaccinated women 1
5. Women ≥65 years with adequate prior normal screening do not require continued screening 1

Special Populations Requiring Modified Approach

Higher-risk women may need more frequent screening (not covered by standard guidelines) 1:

• HIV-positive/immunocompromised women
• History of cervical cancer
• In utero diethylstilbestrol exposure

Cotesting Context

For women 30-65 years 1:

• Preferred: Cotesting (cytology + HPV) every 5 years
• Alternative: Cytology alone every 3 years if cotesting unavailable
• Cotesting not recommended for women 21-29 years

The guiding principle throughout is: similar management for similar cancer risks 1. This ensures consistent, evidence-based care regardless of the specific test combination used to identify the abnormality.